POTENTIAL TARGETS FROM HUMAN (RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES)1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Seq. Identity (%)	View	Dock
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	6 / 12	ALA A  31 VAL A  64 PHE A  80 ASP A  86 LEU A 133 ALA A 143	None	0.70A	45.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	6 / 12	ILE A  10 ALA A  31 VAL A  64 PHE A  80 ASP A  86 LEU A 133	None	0.90A	45.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	6 / 12	ILE A  10 VAL A  18 ALA A  31 VAL A  64 PHE A  80 LEU A 133	None	0.79A	45.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	6 / 12	VAL A  18 ALA A  31 VAL A  64 PHE A  80 LEU A 133 ALA A 143	None	0.67A	45.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	GLY A 617 VAL A 624 ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None	0.86A	25.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	6 / 12	GLY A 370 VAL A 377 ALA A 389 VAL A 419 PHE A 435 LEU A 489	None	0.86A	27.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	6 / 12	GLY A 596 VAL A 603 ALA A 621 VAL A 654 ASP A 677 LEU A 799	None STI  A   3 ( 4.6A) STI  A   3 (-3.5A) STI  A   3 (-4.3A) None STI  A   3 (-4.4A)	0.89A	26.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	6 / 12	ALA A 184 VAL A 220 PHE A 236 LEU A 290 ALA A 319 ASP A 320	None	0.83A	30.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	7 / 12	GLY A 163 VAL A 170 ALA A 184 VAL A 220 PHE A 236 LEU A 290 ALA A 319	None	0.83A	30.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	GLY A 249 VAL A 256 ALA A 269 VAL A 299 LEU A 370 ALA A 380	None GIN  A 600 ( 4.7A) GIN  A 600 (-3.1A) GIN  A 600 (-4.6A) GIN  A 600 (-4.7A) GIN  A 600 (-3.1A)	0.74A	25.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	8 / 12	GLY A  11 VAL A  18 ALA A  31 VAL A  64 PHE A  80 ASP A  86 LEU A 134 ALA A 144	None	0.80A	48.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	7 / 12	GLY A  11 VAL A  64 PHE A  80 ASP A  86 LEU A 134 ALA A 144 ASP A 145	None	0.93A	48.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	7 / 12	ILE A  10 GLY A  11 VAL A  18 ALA A  31 PHE A  80 ASP A  86 LEU A 134	None	1.03A	48.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	7 / 12	GLY A  83 VAL A  90 ALA A 103 VAL A 137 ASP A 160 LEU A 205 ALA A 215	ANP  A1480 ( 4.3A) None ANP  A1480 ( 3.9A) ANP  A1480 (-4.7A) ANP  A1480 (-4.0A) ANP  A1480 ( 4.7A) ANP  A1480 ( 4.1A)	0.92A	26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	7 / 12	ILE A  82 GLY A  83 VAL A  90 ALA A 103 VAL A 137 ASP A 160 LEU A 205	None ANP  A1480 ( 4.3A) None ANP  A1480 ( 3.9A) ANP  A1480 (-4.7A) ANP  A1480 (-4.0A) ANP  A1480 ( 4.7A)	1.21A	26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2vd5	DMPK PROTEIN (Homo sapiens)	6 / 12	VAL A  85 ALA A  98 ASP A 155 THR A 158 LEU A 202 ALA A 212	BI8  A1417 ( 4.7A) BI8  A1417 ( 3.8A) None None BI8  A1417 (-4.8A) BI8  A1417 ( 4.1A)	0.79A	24.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	9 / 12	GLY B  13 ALA B  33 VAL B  72 PHE B  93 HIS B  95 ASP B  99 THR B 102 LEU B 147 ALA B 157	None	0.72A	69.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	7 / 12	GLY B  13 HIS B  95 ASP B  99 THR B 102 LEU B 147 ALA B 157 ASP B 158	None	1.07A	69.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	7 / 12	GLY B  15 ALA B  33 VAL B  72 PHE B  93 ASP B  99 LEU B 147 ALA B 157	None	1.45A	69.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	10 / 12	ILE B  12 GLY B  13 VAL B  20 ALA B  33 VAL B  72 PHE B  93 HIS B  95 THR B 102 LEU B 147 ALA B 157	None	0.93A	69.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	8 / 12	ILE B  12 GLY B  13 VAL B  20 HIS B  95 THR B 102 LEU B 147 ALA B 157 ASP B 158	None	1.29A	69.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	7 / 12	GLY A  69 VAL A  76 ALA A  92 VAL A 125 ASP A 148 THR A 151 LEU A 194	STU  A   1 (-3.3A) None STU  A   1 (-3.3A) None STU  A   1 (-3.8A) None STU  A   1 (-4.6A)	0.87A	29.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3bhh	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II BETA CHAIN (Homo sapiens)	7 / 12	VAL A  28 ALA A  41 VAL A  74 PHE A  90 LEU A 143 ALA A 156 ASP A 157	5CP  A 600 ( 4.4A) 5CP  A 600 (-3.6A) 5CP  A 600 ( 4.7A) 5CP  A 600 ( 4.3A) 5CP  A 600 (-4.4A) 5CP  A 600 ( 3.9A) 5CP  A 600 (-3.5A)	0.77A	30.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3c0i	PERIPHERAL PLASMA MEMBRANE PROTEIN CASK (Homo sapiens)	7 / 12	ILE A  18 GLY A  19 VAL A  26 ALA A  39 VAL A  75 PHE A  91 LEU A 148	3AM  A 338 (-4.5A) None 3AM  A 338 ( 4.1A) 3AM  A 338 (-3.3A) None 3AM  A 338 (-3.6A) 3AM  A 338 (-4.7A)	1.12A	26.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3dak	SERINE/THREONINE-PRO TEIN KINASE OSR1 (Homo sapiens)	7 / 12	ILE A  23 GLY A  24 VAL A  31 ALA A  44 VAL A  76 LEU A 153 ALA A 163	ANP  A   1 (-4.2A) ANP  A   1 (-3.3A) ANP  A   1 (-4.5A) ANP  A   1 ( 3.9A) None None MG  A 296 ( 3.9A)	0.93A	26.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3f2a	PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	6 / 12	GLY A  45 VAL A  52 ALA A  65 ASP A 128 LEU A 174 ASP A 186	985  A   1 ( 3.9A) 985  A   1 (-4.5A) 985  A   1 (-3.5A) 985  A   1 (-4.7A) 985  A   1 (-4.8A) 985  A   1 ( 4.0A)	0.94A	26.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	9 / 12	ILE A  25 GLY A  26 VAL A  33 ALA A  46 VAL A  79 PHE A 103 ASP A 109 LEU A 156 ALA A 166	None	0.83A	36.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	6 / 12	VAL A  79 PHE A 103 ASP A 109 LEU A 156 ALA A 166 ASP A 167	None	0.73A	36.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3mtl	CELL DIVISION PROTEIN KINASE 16 (Homo sapiens)	7 / 12	GLY A 172 VAL A 179 ALA A 192 VAL A 224 PHE A 240 ASP A 246 LEU A 293	FEF  A 668 ( 4.2A) FEF  A 668 (-4.9A) FEF  A 668 (-3.3A) FEF  A 668 (-4.7A) FEF  A 668 ( 4.3A) FEF  A 668 ( 4.3A) FEF  A 668 (-4.2A)	0.85A	39.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3mtl	CELL DIVISION PROTEIN KINASE 16 (Homo sapiens)	7 / 12	VAL A 179 ALA A 192 VAL A 224 PHE A 240 ASP A 246 LEU A 293 ALA A 303	FEF  A 668 (-4.9A) FEF  A 668 (-3.3A) FEF  A 668 (-4.7A) FEF  A 668 ( 4.3A) FEF  A 668 ( 4.3A) FEF  A 668 (-4.2A) FEF  A 668 ( 4.0A)	0.87A	39.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3qfv	CDC42BPB PROTEIN (Homo sapiens)	7 / 12	GLY A  83 VAL A  90 ALA A 103 ASP A 160 THR A 163 LEU A 207 ALA A 217	NM7  A 416 (-3.0A) NM7  A 416 (-3.7A) NM7  A 416 ( 3.7A) None None NM7  A 416 ( 4.2A) NM7  A 416 ( 4.5A)	0.80A	25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3qfv	CDC42BPB PROTEIN (Homo sapiens)	7 / 12	GLY A  83 VAL A  90 ASP A 160 THR A 163 LEU A 207 ALA A 217 ASP A 218	NM7  A 416 (-3.0A) NM7  A 416 (-3.7A) None None NM7  A 416 ( 4.2A) NM7  A 416 ( 4.5A) EDO  A 417 (-3.7A)	0.89A	25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3qfv	CDC42BPB PROTEIN (Homo sapiens)	7 / 12	ILE A  82 GLY A  83 VAL A  90 ALA A 103 ASP A 160 THR A 163 LEU A 207	None NM7  A 416 (-3.0A) NM7  A 416 (-3.7A) NM7  A 416 ( 3.7A) None None NM7  A 416 ( 4.2A)	1.10A	25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	6 / 12	GLY A 362 VAL A 369 ALA A 382 ASP A 440 LEU A 486 ALA A 496	07U  A   1 ( 4.2A) 07U  A   1 (-4.8A) 07U  A   1 (-3.3A) 07U  A   1 (-3.9A) 07U  A   1 (-4.3A) 07U  A   1 ( 4.0A)	0.86A	27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	6 / 12	VAL A 552 ALA A 570 VAL A 601 PHE A 617 ASP A 624 LEU A 686	None 0F4  A 902 (-3.2A) None 0F4  A 902 (-3.4A) None 0F4  A 902 (-4.5A)	0.86A	27.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 12	GLY A  76 VAL A  83 ALA A  96 VAL A 128 HIS A 146 LEU A 198	ANP  A 401 ( 3.7A) ANP  A 401 ( 4.3A) ANP  A 401 (-3.2A) CHU  A 403 (-4.2A) ANP  A 401 ( 4.9A) ANP  A 401 (-4.8A)	0.87A	31.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	7 / 12	ILE A  10 GLY A  11 VAL A  18 ALA A  31 VAL A  64 PHE A  80 LEU A 133	D15  A 500 (-4.2A) D15  A 500 (-3.8A) D15  A 500 (-4.6A) D15  A 500 (-3.4A) None D15  A 500 ( 4.3A) D15  A 500 (-4.5A)	0.75A	35.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	6 / 12	VAL A 568 ALA A 586 VAL A 617 PHE A 633 ASP A 640 LEU A 699	None LTI  A1839 (-3.3A) None LTI  A1839 (-3.5A) None LTI  A1839 (-4.2A)	0.86A	27.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4bbm	CYCLIN-DEPENDENT KINASE-LIKE 2 (Homo sapiens)	6 / 12	VAL A  18 ALA A  31 VAL A  64 PHE A  80 LEU A 133 ASP A 144	None TC0  A 500 (-3.5A) TC0  A 500 (-4.7A) TC0  A 500 (-3.4A) TC0  A 500 (-4.3A) TC0  A 500 (-4.8A)	0.71A	33.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	6 / 12	GLY A  43 VAL A  50 ALA A  63 VAL A  94 LEU A 164 ALA A 174	XZN  A1317 ( 4.9A) XZN  A1317 ( 4.7A) XZN  A1317 (-3.5A) XZN  A1317 (-4.4A) XZN  A1317 (-4.7A) XZN  A1317 ( 4.3A)	0.93A	28.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4bgq	CYCLIN-DEPENDENT KINASE-LIKE 5 (Homo sapiens)	6 / 12	GLY A  20 VAL A  27 ALA A  40 VAL A  73 PHE A  89 LEU A 142	None 38R  A1000 ( 4.8A) 38R  A1000 (-3.4A) None 38R  A1000 ( 3.8A) 38R  A1000 ( 4.5A)	0.68A	35.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	6 / 12	VAL A 671 ALA A 684 VAL A 721 ASP A 744 LEU A 789 ALA A 799	AGS  A1985 (-4.6A) AGS  A1985 (-3.5A) None AGS  A1985 (-4.0A) AGS  A1985 (-4.8A) AGS  A1985 ( 4.5A)	0.74A	26.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	6 / 12	ALA A 588 VAL A 620 ASP A 643 THR A 646 LEU A 690 ASP A 701	GUI  A 901 (-3.4A) None GUI  A 901 ( 4.8A) GUI  A 901 ( 3.8A) GUI  A 901 (-4.3A) GUI  A 901 ( 4.1A)	0.86A	22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	7 / 12	ILE A 567 GLY A 568 ALA A 588 VAL A 620 ASP A 643 THR A 646 LEU A 690	GUI  A 901 (-4.0A) GUI  A 901 ( 4.3A) GUI  A 901 (-3.4A) None GUI  A 901 ( 4.8A) GUI  A 901 ( 3.8A) GUI  A 901 (-4.3A)	1.01A	22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	7 / 12	ILE A 567 GLY A 568 VAL A 575 ALA A 588 VAL A 620 ASP A 643 LEU A 690	GUI  A 901 (-4.0A) GUI  A 901 ( 4.3A) GUI  A 901 (-4.5A) GUI  A 901 (-3.4A) None GUI  A 901 ( 4.8A) GUI  A 901 (-4.3A)	1.01A	22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4ez5	CYCLIN-DEPENDENT KINASE 6 (Homo sapiens)	7 / 12	GLY A  20 VAL A  27 VAL A  77 PHE A  98 ASP A 104 THR A 106 LEU A 152	None None 0RS  A 900 (-4.4A) 0RS  A 900 (-4.5A) 0RS  A 900 (-4.2A) None 0RS  A 900 (-4.3A)	1.44A	100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4ez5	CYCLIN-DEPENDENT KINASE 6 (Homo sapiens)	12 / 12	ILE A  19 GLY A  20 VAL A  27 ALA A  41 VAL A  77 PHE A  98 HIS A 100 ASP A 104 THR A 107 LEU A 152 ALA A 162 ASP A 163	0RS  A 900 (-4.1A) None None 0RS  A 900 ( 3.7A) 0RS  A 900 (-4.4A) 0RS  A 900 (-4.5A) 0RS  A 900 (-4.1A) 0RS  A 900 (-4.2A) 0RS  A 900 (-4.2A) 0RS  A 900 (-4.3A) 0RS  A 900 (-3.6A) 0RS  A 900 (-3.6A)	0.66A	100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	7 / 12	GLY A 516 VAL A 523 ALA A 541 VAL A 572 PHE A 588 ASP A 595 LEU A 656	None	0.91A	27.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	6 / 12	GLY A1123 VAL A1130 ALA A1148 VAL A1180 ASP A1203 LEU A1256	0UV  A1501 ( 4.3A) 0UV  A1501 (-4.5A) 0UV  A1501 (-3.4A) 0UV  A1501 ( 4.9A) 0UV  A1501 ( 4.6A) 0UV  A1501 (-4.6A)	0.94A	24.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4fzd	SERINE/THREONINE-PRO TEIN KINASE MST4 (Homo sapiens)	6 / 12	ILE B  30 GLY B  31 VAL B  38 ALA B  51 LEU B 151 ALA B 161	GOL  B1000 (-4.1A) None None GOL  B1000 ( 4.3A) GOL  B1000 ( 4.4A) None	0.64A	26.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	6 / 12	GLY A 829 VAL A 836 ALA A 853 VAL A 884 LEU A 956 ALA A 966	19S  A1201 (-3.7A) 19S  A1201 (-4.4A) 19S  A1201 (-3.3A) None 19S  A1201 (-4.5A) 19S  A1201 ( 4.1A)	0.83A	26.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	6 / 12	ALA A 648 VAL A 685 ASP A 708 LEU A 753 ALA A 763 ASP A 764	None	0.93A	27.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	7 / 12	GLY A 617 VAL A 624 ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None None P30  A1001 (-3.4A) None P30  A1001 (-3.7A) None P30  A1001 (-4.6A)	0.81A	23.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	7 / 12	GLY A 617 VAL A 624 ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None P30  A1001 ( 4.8A) P30  A1001 (-3.5A) None P30  A1001 ( 4.3A) None P30  A1001 (-4.3A)	0.76A	28.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	7 / 12	GLY A  11 VAL A  18 ALA A  31 VAL A  64 PHE A  80 LEU A 135 ALA A 145	None	0.88A	45.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	7 / 12	VAL A  18 ALA A  31 VAL A  64 ASP A  86 LEU A 135 ALA A 145 ASP A 146	None	0.98A	45.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	7 / 12	VAL A  18 ALA A  31 VAL A  64 PHE A  80 ASP A  86 LEU A 135 ALA A 145	None	0.69A	45.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	6 / 12	GLY A 470 VAL A 477 ALA A 488 LEU A 595 ALA A 605 ASP A 606	4CV  A 801 ( 3.9A) None 4CV  A 801 (-3.5A) 4CV  A 801 (-4.4A) 4CV  A 801 ( 3.9A) 4CV  A 801 (-3.5A)	0.71A	26.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	6 / 12	ILE A 165 GLY A 166 VAL A 173 ALA A 186 PHE A 238 LEU A 294	4E1  A 505 ( 4.6A) 4E1  A 505 (-3.5A) 4E1  A 505 (-4.5A) 4E1  A 505 (-3.5A) 4E1  A 505 (-4.2A) None	0.83A	29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	6 / 12	ILE A 165 GLY A 166 VAL A 173 ALA A 186 VAL A 222 PHE A 238	4E1  A 505 ( 4.6A) 4E1  A 505 (-3.5A) 4E1  A 505 (-4.5A) 4E1  A 505 (-3.5A) None 4E1  A 505 (-4.2A)	0.88A	29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	6 / 12	VAL A  30 ALA A  44 VAL A  76 ASP A  99 LEU A 145 ALA A 164	51W  A 401 ( 4.3A) 51W  A 401 (-3.4A) None 51W  A 401 (-3.8A) 51W  A 401 (-4.5A) None	0.69A	29.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	6 / 12	GLY A 600 VAL A 607 ALA A 625 VAL A 658 ASP A 681 LEU A 825	None 748  A1001 ( 4.7A) 748  A1001 (-3.7A) 748  A1001 ( 4.8A) None 748  A1001 (-4.3A)	0.84A	26.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5idn	CYCLIN-DEPENDENT KINASE 8 (Homo sapiens)	6 / 12	GLY A  28 ALA A  50 PHE A  97 ASP A 103 LEU A 158 ALA A 172	6A7  A 401 (-3.6A) 6A7  A 401 (-3.3A) 6A7  A 401 (-3.8A) 6A7  A 401 ( 4.9A) 6A7  A 401 (-4.8A) 6A7  A 401 ( 4.1A)	0.83A	32.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5idn	CYCLIN-DEPENDENT KINASE 8 (Homo sapiens)	6 / 12	GLY A  28 VAL A  35 ALA A  50 PHE A  97 LEU A 158 ALA A 172	6A7  A 401 (-3.6A) 6A7  A 401 ( 4.5A) 6A7  A 401 (-3.3A) 6A7  A 401 (-3.8A) 6A7  A 401 (-4.8A) 6A7  A 401 ( 4.1A)	0.78A	32.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	6 / 12	GLY A  23 VAL A  30 ALA A  43 VAL A  74 ALA A 153 ASP A 154	None 6G2  A 901 ( 4.9A) 6G2  A 901 (-3.2A) None 6G2  A 901 ( 4.2A) 6G2  A 901 (-3.4A)	0.94A	26.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	6 / 12	VAL A  30 ALA A  43 VAL A  74 LEU A 143 ALA A 153 ASP A 154	6G2  A 901 ( 4.9A) 6G2  A 901 (-3.2A) None 6G2  A 901 (-4.7A) 6G2  A 901 ( 4.2A) 6G2  A 901 (-3.4A)	0.86A	26.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	7 / 12	ILE A 396 GLY A 397 VAL A 404 ALA A 417 VAL A 449 ASP A 472 LEU A 518	GUI  A 701 (-4.1A) GUI  A 701 ( 3.8A) GUI  A 701 (-4.4A) GUI  A 701 ( 3.9A) None None GUI  A 701 (-4.4A)	1.14A	31.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5loh	SERINE/THREONINE-PRO TEIN KINASE GREATWALL,SERINE/THR EONINE-PROTEIN KINASE GREATWALL (Homo sapiens)	6 / 12	ILE A  41 VAL A  49 ALA A  60 VAL A  94 ASP A 117 LEU A 163	STU  A 901 (-4.3A) None STU  A 901 (-3.3A) None STU  A 901 (-4.2A) STU  A 901 (-4.5A)	0.74A	27.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5lxd	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 2 (Homo sapiens)	6 / 12	ILE A 155 GLY A 156 VAL A 163 ALA A 176 PHE A 228 LEU A 282	7A7  A 501 ( 4.3A) 7A7  A 501 (-3.2A) 7A7  A 501 (-4.4A) 7A7  A 501 (-3.5A) 7A7  A 501 (-3.7A) 7A7  A 501 (-4.9A)	0.86A	26.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5myv	SRSF PROTEIN KINASE 2,SRSF PROTEIN KINASE 2 (Homo sapiens)	6 / 12	GLY A  99 VAL A 106 ALA A 119 VAL A 157 PHE A 177 LEU A 232	W4A  A 716 ( 4.0A) W4A  A 716 ( 4.7A) W4A  A 716 ( 3.9A) DMS  A 717 (-4.3A) DMS  A 717 ( 3.9A) None	0.94A	26.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	7 / 12	ILE A  98 GLY A  99 ALA A 119 VAL A 153 ASP A 176 LEU A 221 ALA A 231	None	1.13A	26.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	7 / 12	ILE A  98 VAL A 106 ALA A 119 VAL A 153 ASP A 176 LEU A 221 ALA A 231	None	1.13A	26.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	7 / 12	GLY A 734 VAL A 787 PHE A 813 ASP A 819 LEU A 866 ALA A 876 ASP A 877	CJM  A1102 (-3.4A) None CJM  A1102 ( 4.4A) CJM  A1102 (-4.1A) CJM  A1102 (-4.4A) CJM  A1102 (-3.6A) MG  A1101 (-2.5A)	0.96A	16.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	8 / 12	ILE A 733 GLY A 734 ALA A 754 VAL A 787 PHE A 813 ASP A 819 LEU A 866 ALA A 876	CJM  A1102 (-3.4A) CJM  A1102 (-3.4A) CJM  A1102 (-3.1A) None CJM  A1102 ( 4.4A) CJM  A1102 (-4.1A) CJM  A1102 (-4.4A) CJM  A1102 (-3.6A)	1.03A	16.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	8 / 12	ILE A 733 VAL A 741 ALA A 754 VAL A 787 PHE A 813 ASP A 819 LEU A 866 ALA A 876	CJM  A1102 (-3.4A) None CJM  A1102 (-3.1A) None CJM  A1102 ( 4.4A) CJM  A1102 (-4.1A) CJM  A1102 (-4.4A) CJM  A1102 (-3.6A)	0.91A	16.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	6bql	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	6 / 12	VAL A 179 ALA A 192 VAL A 249 PHE A 267 LEU A 319 ALA A 329	BI9  A 501 ( 4.8A) BI9  A 501 (-3.3A) None BI9  A 501 ( 4.2A) BI9  A 501 (-4.7A) NH4  A 506 ( 3.7A)	0.90A	13.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	GLY A 135 VAL A 142 ALA A 155 VAL A 212 PHE A 230 LEU A 282 ALA A 292	H1N  A 501 ( 3.8A) H1N  A 501 (-4.4A) H1N  A 501 (-3.4A) H1N  A 501 (-4.9A) H1N  A 501 (-3.7A) H1N  A 501 (-4.8A) H1N  A 501 ( 3.9A)	0.75A	15.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	7 / 12	ILE A 134 GLY A 135 VAL A 142 ALA A 155 VAL A 212 PHE A 230 LEU A 282	H1N  A 501 (-4.3A) H1N  A 501 ( 3.8A) H1N  A 501 (-4.4A) H1N  A 501 (-3.4A) H1N  A 501 (-4.9A) H1N  A 501 (-3.7A) H1N  A 501 (-4.8A)	1.05A	15.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	1jm7	BRCA1-ASSOCIATED RING DOMAIN PROTEIN 1 BREAST CANCER TYPE 1 SUSCEPTIBILITY PROTEIN (Homo sapiens)	3 / 3	LYS B 110 GLN A  19 ASN A  16	None	0.96A	16.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	1mco	IGG1 MCG INTACT ANTIBODY (HEAVY CHAIN) (Homo sapiens)	3 / 3	LYS H 323 GLN H 296 ASN H 297	None	0.84A	20.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	1rw2	ATP-DEPENDENT DNA HELICASE II, 80 KDA SUBUNIT (Homo sapiens)	3 / 3	LYS A  76 GLN A  57 ASN A  39	None	0.83A	19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	1tfx	TISSUE FACTOR PATHWAY INHIBITOR (Homo sapiens)	3 / 3	LYS C   1 GLN C  26 ASN C  24	None	1.08A	9.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	2oz4	FAB FRAGMENT, HEAVY CHAIN INTERCELLULAR ADHESION MOLECULE 1 (Homo sapiens; Mus musculus)	3 / 3	LYS H  99 GLN A 436 ASN A 397	None	0.71A	21.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	3c10	HISTONE DEACETYLASE 7A (Homo sapiens)	3 / 3	LYS A 658 GLN A 826 ASN A 829	None	1.06A	19.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	3iiw	POLYCOMB PROTEIN EED (Homo sapiens)	3 / 3	LYS A 322 GLN A 360 ASN A 381	None	0.97A	19.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	3ksy	SON OF SEVENLESS HOMOLOG 1 (Homo sapiens)	3 / 3	LYS A 534 GLN A 500 ASN A 502	None	0.96A	13.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	3lm5	SERINE/THREONINE-PRO TEIN KINASE 17B (Homo sapiens)	3 / 3	LYS A  62 GLN A 162 ASN A 163	QUE  A   1 (-4.1A) None None	0.81A	25.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	4ez5	CYCLIN-DEPENDENT KINASE 6 (Homo sapiens)	3 / 3	LYS A  43 GLN A 149 ASN A 150	0RS  A 900 (-3.3A) None None	1.08A	100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	4jvs	RAS-RELATED PROTEIN RAB-1A (Homo sapiens)	3 / 3	LYS B  24 GLN B 104 ASN B 101	GDP  B 400 ( 2.6A) None None	0.68A	19.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	4pbx	RECEPTOR-TYPE TYROSINE-PROTEIN PHOSPHATASE S (Homo sapiens)	3 / 3	LYS A  35 GLN A 110 ASN A 111	None	1.02A	20.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	4tnb	G PROTEIN-COUPLED RECEPTOR KINASE 5 (Homo sapiens)	3 / 3	LYS A  15 GLN A 512 ASN A 513	None	0.57A	21.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	5crj	TRANSCRIPTION TERMINATION FACTOR 1, MITOCHONDRIAL (Homo sapiens)	3 / 3	LYS O 312 GLN O 344 ASN O 348	None	1.01A	24.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	5fah	KALLIKREIN-7 (Homo sapiens)	3 / 3	LYS A  84 GLN A  39 ASN A  38	None 5VT  A 302 (-4.4A) None	1.08A	21.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	5fn3	PRESENILIN-1 (Homo sapiens)	3 / 3	LYS B 101 GLN B 454 ASN B 405	None	1.09A	22.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_2 (CYCLIN-DEPENDENT KINASE 6)	5mqi	PROTEIN TIMELESS HOMOLOG,PROTEIN TIMELESS HOMOLOG (Homo sapiens)	3 / 3	LYS A 441 GLN A 229 ASN A 230	None	1.08A	21.39